Professional Metabolic Supplement Manufacturer

Our Products

Product Display

S-NAD

CAS No.: 4090-29-3
Purity: ≥ 95%

BONTAC is the Leader of Global Industry

What We Do

Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.

As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.

In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.

more>>

Our Blog

Latest News

17 Jun 2024

Autophagy-NAD Axis as a Target for Therapeutic Interventions in NPC1 Disease

Introduction Targeting the autophagy-NAD axis has been reported be a viable therapeutic strategy for Niemann-Pick type C1 (NPC1) disease. The study suggests that both pharmacological rescue of autophagy deficiency and

14 Jun 2024

Hello! 2024 CPHI

On June 19th~21st, 2024, Chemical Pharmaceutical Ingredient (CPHI) Exhibition will be held in Shanghai New International Expo Center, China. BONTAC will display premium raw materials of coenzyme and natural products

12 Jun 2024

Rh2 and Ca(OH)2 Combo: Promising Treatment for Root Canal Infections

Introduction Apical periodontitis, an inflammatory disease affecting tooth apex tissues, is triggered by oral pathogens infecting the root canal. One of the main reason for endodontic treatment failure is Enterococcus

07 Jun 2024

The Possible Use of Stevioside as a Therapeutic Alternative in Amoebiasis

Introduction Amoebiasis has emerged as the third most common cause of death by parasites worldwide after malaria and schistosomiasis infections. According to the report of World Health Organization, over 40 milli

30 May 2024

Transcriptome and Metabolome Profiling on the Potential of NMN/NR Against NAFLD

Introduction Disturbance in hepatic NAD+ metabolism has been manifested as a key factor in the initiation and progression of nonalcoholic fatty liver disease (NAFLD), one of the most co

29 May 2024

Ginsenoside Rg3: A Promising Therapeutic Agent for Traumatic Brain Injury

Introduction According to the 2017 Commission on Traumatic Brain Injury (TBI), TBI remains one of the top three causes of injury-related death and disability up to 2030. There are 50~60

28 May 2024

NMN Supplementation: A Shield Against Doxorubicin-Induced Multi-Organ Fibrosis

Introduction In clinical settings, doxorubicin (DOX) is an effective broad-spectrum anti-cancer drug in chemotherapy for various tumors, including hematological malignancies and solid tumors such as leu

27 May 2024

Guarding Your Liver Against Nicotine and Coca-Cola™-Induced Steatosis with NR

Introduction Cigarettes containing nicotine (Nic) and sugar-sweetened beverages (SSBs) with high fructose corn syrup (HFCS) have been uncovered to induce hepatic steatosis, which are the risk factors for the developme

23 May 2024

20(S)-Ginsenoside Rh2: A Promising Adjuvant Treatment for Acute Promyelocytic Leukemia

Introduction Acute promyelocytic leukemia (APL), the M3 type of acute myeloid leukemia (AML), typically relies on all-trans retinoic acid (ATRA) as its primary treatment. While APL patients treated with

22 May 2024

A Key Role for NMN in Alleviating Organelle Miscommunication in HFD Mouse Liver

Introduction Recent research unveils that hepatic insulin resistance (IR) and steatosis in obesity have a strong association with endoplasmic reticulum (ER)-mitochondria miscommunication. Notably,

“Bonzyme”Whole-enzymatic method, environmental-friendly

Original NMN Supplier for David Sinclair Team

Bontac keeps cultivating deeply on the field of green biosynthesis of coenzymes and nature products

Bontac is the first enterprise in the world to achieve mass production of NMN

Product Display

What We Do

Bontac lnternational Patents

14

90

170

200

Inquiry

Our Certifications